Results For "PRV-sale"

1 News Found

Sun Pharma Advanced Research Company to sell priority review voucher for $195 Million

R&D | April 30, 2026

Sun Pharma Advanced Research Company to sell priority review voucher for $195 Million

SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth

Latest Stories

BD, Suttons Creek partner to streamline combination product development

RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth

GSK wins regulatory boost for once-monthly liver drug efimosfermin in MASH push

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India

Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India

Kavinder Beniwal Chief Operational Officer, Motorica India

Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics

Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics

Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.

Packaging